Top

Clinical Drug Investigation

Published in:

01-05-2009 | Original Research Article

RETRACTED ARTICLE: Anti-Fracture Efficacy of Risedronic Acid in Men

A Meta-Analysis of Randomized Controlled Trials

Authors: Zhao-Ming Zhong, Dr Jian-Ting Chen

Published in: Clinical Drug Investigation | Issue 5/2009

Abstract

Background and objective: Male osteoporosis is an important public health issue and remains undertreated. We performed this meta-analysis to clarify the anti-fracture efficacy of risedronic acid in men.

Methods: Randomized controlled trials (RCTs) in men receiving risedronic acid or placebo published between 1980 and September 2008 were searched for in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Studies with a follow-up of at least 12 months and providing the incidence of fractures were considered for inclusion in the review. Two independent reviewers assessed the methodological quality of the included studies and performed data extraction. Analysis of pooled data was carried out using Revman 4.2 software.

Results: Four RCTs met the inclusion criteria and permitted a pooled estimate of effectiveness. Relative risk with 95% confidence intervals for pooled effect under fixed effects model were: 0.31 (0.16, 0.60) for vertebral fractures and 0.40 (0.23, 0.70) for nonvertebral fractures, suggesting a 69% risk reduction of vertebral fractures and a 60% risk reduction of nonvertebral fracture with risedronic acid treatment in men.

Conclusion: The results of this meta-analysis show that risedronic acid treatment is associated with a reduced risk of fractures in men.

Boonen S, Kaufman JM, Goemaere S, et al. The diagnosis and treatment of male osteoporosis: defining, assessing, and preventing skeletal fragility in men. Eur J Intern Med 2007; 18: 6–17PubMed

Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003; 67: 1521–6PubMed

Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878–82PubMed

Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005; 16: 953–62PubMed

Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162: 2217–22PubMed

Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010–8PubMed

Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1–34PubMedPubMedCentral

Clemmesen B, Ravn P, Zegels B, et al. A 2-year phase II study with 1 year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997; 7: 488–95PubMed

Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91PubMed

10.

Ste-Marie LG, Sod E, Johnson T, et al. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 469–76PubMed

11.

Palomba S, Orio Jr F, Manguso F, et al. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005; 16: 1141–9PubMed

12.

McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–40PubMed

13.

Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007; 68: 911–5

14.

Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165: 1743–8

15.

Ringe JD, Faber H, Farahmand P, et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26: 427–31PubMed

16.

Reid DM, Adami S, Devogelaer JP, et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69: 242–7PubMed

17.

Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. In: The Cochrane library. Issue 4. Chichester, UK: John Wiley & Sons, Ltd., 2006

18.

Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665–77PubMed

19.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88

20.

Majima T, Komatsu Y, Doi K, et al. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves’ disease. J Bone Miner Metab 2006; 24: 105–13PubMed

21.

Majima T, Shimatsu A, Komatsu Y, et al. Efficacy of risedronate in Japanese male patients with primary osteoporosis. Intern Med 2008; 47: 717–23PubMed

22.

Kanaji A, Higashi M, Namisato M, et al. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Lepr Rev 2006; 77: 147–53PubMed

23.

Hosking DJ, Geusens P, Rizzoli R. Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM 2005; 98: 403–13PubMed

24.

Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med 2003; 254: 105–13PubMed

25.

Olszynski WP, Shawn Davison K, Adachi JD, et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004; 26: 15–28PubMed

26.

Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16: 87–116PubMed

27.

Khan AA, Hodsman AB, Papaioannou A, et al. Management of osteoporosis in men: an update and case example. CMAJ 2007; 176: 345–8PubMedPubMedCentral

28.

Sato Y, Kaji M, Tsuru T, et al. Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 2001; 182: 89–93PubMed

29.

Ramnemark A, Nilsson M, Borssen B, et al. Stroke, a major and increasing risk factor for femoral neck fracture. Stroke 2000; 31: 1572–7PubMed

30.

Ringe JD, Orwoll E, Daifotis A, et al. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 2002; 13: 195–9PubMed

31.

Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52PubMed

32.

Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000; 85: 1895–900PubMed

33.

Shiraki M, Fukunaga M, Kushida K, et al. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 2003; 14: 225–34PubMed

34.

Kushida K, Fukunaga M, Kishimoto H, et al. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 2004; 22: 469–78PubMed

35.

Ogura Y, Gonsho A, Cyong JC, et al. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 2004; 22: 111–9PubMed

36.

Nakamura T. Current situation of osteoporosis treatment in Japan: from the aspect of fracture prevention. Geriatr Gerontol Int 2004; 4: S69–71

37.

Swaminathan R. Nutritional factors in osteoporosis. Int J Clin Pract 1999; 53: 540–8PubMed

38.

Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly woman. N Engl J Med 1992; 327: 1637–42PubMed

39.

Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2PubMedPubMedCentral

40.

Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6PubMed

41.

Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004; 15: 511–9PubMed

42.

Sato Y, Oizumi K, Kuno H, et al. Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients. Bone 1999; 24: 271–5PubMed

43.

Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 1997; 49: 1273–8PubMed

44.

Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007; 18: 25–34PubMed

45.

Curtis JR, Westfall AO, Cheng H, et al. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 2008 Oct 23 [Epub ahead of publication]

46.

Miller PD, Schnitzer T, Emkey R, et al. Weekly oral alendronic acid in male osteoporosis. Clin Drug Invest 2004; 24: 333–41

47.

Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005; 6: 39PubMedPubMedCentral

48.

Guyatt G, Rennie D, editors. Users’ guides to the medical literature: a manual for evidence-based clinical practice. Chicago: AMA Press, 2001

Title: RETRACTED ARTICLE: Anti-Fracture Efficacy of Risedronic Acid in Men
A Meta-Analysis of Randomized Controlled Trials
Authors: Zhao-Ming Zhong
Dr Jian-Ting Chen
Publication date: 01-05-2009
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 5/2009
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200929050-00007

Keynote webinar | Spotlight on medication adherence

Springer Medicine

RETRACTED ARTICLE: Anti-Fracture Efficacy of Risedronic Acid in Men

A Meta-Analysis of Randomized Controlled Trials

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

HairMax LaserComb® Laser Phototherapy Device in the Treatment of Male Androgenetic Alopecia

Effect of Ivabradine, a Novel Antianginal Agent, on Driving Performance

Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain

Combination Therapy with Candesartan Cilexetil 32mg and Hydrochlorothiazide 25mg Provides the Full Additive Antihypertensive Effect of the Components

Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4mg/day to Solifenacin Treatment

Pharmacokinetics of Two 6-Day Frovatriptan Dosing Regimens Used for the Short-Term Prevention of Menstrual Migraine